Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast Cancer

HER2+ De Novo MBC: Neratinib Vs Lapatinib Plus CapecitabineПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

Peri-operative lapatinib has profound antiproliferative effect in early breast cancerПодробнее

Cancer and Us gets a port for breast cancer HER2 Positive Chemo treatmentПодробнее

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast CancerПодробнее

Tucatinib Combination Improved Survival in HER2–Positive Breast CancerПодробнее

ASCO 2013: Lapatinib in combination with chemotherapy in breast cancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Pyrotinib Plus Capecitabine for HER2 Metastatic Breast CancerПодробнее

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain MetastasesПодробнее

Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain MetastasesПодробнее

LapatinibПодробнее

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic...Подробнее

Role of Lapatinib in HER2-Positive Breast CancerПодробнее

Systemic Therapies Shown to be Effective in HER2-Positive Breast CancerПодробнее

Survival in premenopausal HR+/HER2- breast cancer with micro-metastasis and 21-gene scoreПодробнее

Tesetaxel Plus Capecitabine for Patients With Metastatic Breast CancerПодробнее

Dr. Tripathy on Determining the Best HER2 Targeted TherapyПодробнее

Journal Highlight: Long-term Survival From Breast Cancer Brain Metastases in the Era of ModernПодробнее